Pulmonary hypertension in congenital shunts;Hipertensión pulmonar en los cortocircuitos congénitos

Revista Espanola de Cardiologia

Volumn 63, Issue 10, 2010, Pages 1179-1193

  Beghetti, Maurice ^a   Tissot, Cecile ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Congenital heart disease; Congenital shunts; Pulmonary hypertension

Indexed keywords

EISENMENGER COMPLEX; FOLLOW UP; FONTAN PROCEDURE; HEART LEFT RIGHT SHUNT; HUMAN; LONG TERM CARE; LUNG CIRCULATION; LUNG VASCULAR RESISTANCE; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PULMONARY HYPERTENSION; REVIEW; SYSTEMIC PULMONARY SHUNT;

EISENMENGER COMPLEX; HEART DEFECTS, CONGENITAL; HUMANS; HYPERTENSION, PULMONARY; INFANT; INFANT, NEWBORN; TREATMENT OUTCOME;

EID: 78649249656     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1016/S0300-8932(10)70250-5     Document Type: Review

References (80)

1. N. Gali, M.M. Hoeper, M. Humbert, A. Torbicki, J.L. Vachiery, and J.A. Barberá Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT) Eur Heart J 30 2009 2493 2537
2. M. Beghetti, and N. Gali Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension J Am Coll Cardiol 53 2009 733 740
3. M. Beghetti Fontan and the pulmonary circulation: a potential role for new pulmonary hypertension therapies Heart 90 2010 911 916
4. M.G. Duffels, P.M. Engelfriet, R.M. Berger, R.L. Van Loon, E. Hoendermis, and J.W. Vriend Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry Int J Cardiol 120 2007 198 204
5. N. Gali, A. Manes, M. Palazzini, L. Negro, A. Marinelli, and S. Gambetti Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger's syndrome Drugs 68 2008 1049 1066
6. G. Simonneau, I.M. Robbins, M. Beghetti, R.N. Channick, M. Delcroix, and C.P. Denton Updated clinical classification of pulmonary hypertension J Am Coll Cardiol 54 Suppl 1 2009 S43 S54
7. M. Beghetti Congenital heart disease and pulmonary hypertension Rev Port Cardiol 23 2004 273 281
8. R.M. Berger Pulmonary hypertension associated with congenital cardiac disease Cardiol Young 19 2009 311 314
9. I. Schulze-Neick, and M. Beghetti Classifying pulmonary hypertension in the setting of the congenitally malformed heart - cleaning up a dog's dinner Cardiol Young 18 2008 22 25
10. N. Gali, A. Torbicki, R. Barst, P. Dartevelle, S. Haworth, and T. Higenbottam Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology Eur Heart J 25 2004 2243 2278
11. S. Viswanathan, and R.K. Kumar Assessment of operability of congenital cardiac shunts with increased pulmonary vascular resistance Catheter Cardiovasc Interv 71 2008 665 670
12. A.A. Lopes, and P.W. O'Leary Measurement, interpretation and use of haemodynamic parameters in pulmonary hypertension associated with congenital cardiac disease Cardiol Young 19 2009 431 435
13. S.G. Haworth, and A.A. Hislop Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001-2006 Heart 95 2009 312 317
14. T.M. Giglia, and T. Humpl Preoperative pulmonary hemodynamics and assessment of operability: is there a pulmonary vascular resistance that precludes cardiac operation? Pediatr Crit Care Med 11 Suppl 2010 S57 S69
15. S.G. Haworth Pulmonary vascular disease in different types of congenital heart disease Br Heart J 52 1984 557 571
16. C. Frescura, G. Thiene, M. Giulia Gagliardi, A. Mazzucco, P.A. Pellegrino, and L. Daliento Is lung biopsy useful for surgical decision making in congenital heart disease? Eur J Cardiothorac Surg 5 1991 118 122
17. M. Berner, M. Beghetti, I. Spahr-Schopfer, I. Oberhansli, and B. Friedli Inhaled nitric oxide to test the vasodilator capacity of the pulmonary vascular bed in children with long-standing pulmonary hypertension and congenital heart disease Am J Cardiol 77 1996 532 535
18. D.T. Balzer, H.W. Kort, R.W. Day, H.M. Corneli, J.P. Kovalchin, and B.C. Cannon Inhaled nitric oxide as a preoperative test (INOP Test I): the INOP Test Study Group Circulation 106 Suppl 1 2002 I76 I81
19. M. Levy, C. Maurey, D.S. Celermajer, P.R. Vouhe, C. Danel, and D. Bonnet Impaired apoptosis of pulmonary endothelial cells is associated with intimal proliferation and irreversibility of pulmonary hypertension in congenital heart disease J Am Coll Cardiol 49 2007 803 810 (Pubitemid 46240714)
20. D.M. Smadja, P. Gaussem, L. Mauge, D. Israel-Biet, F. Dignat-George, and S. Peyrard Circulating endothelial cells: a new candidate biomarker of irreversible pulmonary hypertension secondary to congenital heart disease Circulation 119 2009 374 381
21. D.M. Smadja, P. Gaussem, L. Mauge, R. Lacroix, S. Gandrille, and V. Remones Comparison of endothelial biomarkers according to reversibility of pulmonary hypertension secondary to congenital heart disease Pediatr Cardiol 131 2010 657 662
22. K. Dimopoulos, A. Peset, and M.A. Gatzoulis Evaluating operability in adults with congenital heart disease and the role of pretreatment with targeted pulmonary arterial hypertension therapy Int J Cardiol 129 2008 163 171
23. M. Humbert, O. Sitbon, and G. Simonneau Treatment of pulmonary arterial hypertension N Engl J Med 351 2004 1425 1436
24. N. Gali, M. Beghetti, M. Gatzoulis, J. Granton, R. Berger, and A. Lauer Breathe-5: bosentan improves hemodynamics and exercise capacity in the first randomized placebo-controlled trial in eisenmenger physiology Chest 128 2005 S496
25. H. Yamauchi, S. Yamaki, M. Fujii, Y. Saji, M. Ochi, and K. Shimizu Atrial septal defect with borderline pulmonary vascular disease: surgery and long-term oral prostacyclin therapy for recalcitrant pulmonary hypertension Jpn J Thorac Cardiovasc Surg 52 2004 213 216
26. A. Eicken, G. Balling, H.P. Gildein, T. Genz, H. Kaemmerer, and J. Hess Transcatheter closure of a non-restrictive patent ductus arteriosus with an Amplatzer muscular ventricular septal defect occluder Int J Cardiol 117 2007 e40 e42
27. M. Schwerzmann, M. Zafar, P.R. McLaughlin, D.W. Chamberlain, G. Webb, and J. Granton Atrial septal defect closure in a patient with " irreversible" pulmonary hypertensive arteriopathy Int J Cardiol 110 2006 104 107
28. K. Hoetzenecker, H.J. Ankersmit, D. Bonderman, W. Hoetzenecker, R. Seitelberger, and W. Klepetko Atrial septal defect repair after a 10-month treatment with bosentan in a patient with severe pulmonary arterial hypertension: a case report J Thorac Cardiovasc Surg 137 2009 760 761
29. I. Adatia, and M. Beghetti Early postoperative care of patients with pulmonary hypertension associated with congenital cardiac disease Cardiol Young 19 2009 315 319
30. K. Bando, M.W. Turrentine, T.G. Sharp, Y. Sekine, T.X. Aufiero, and K. Sun Pulmonary hypertension after operations for congenital heart disease: analysis of risk factors and management J Thorac Cardiovasc Surg 112 1996 1600 1607
31. W.E. Hopkins, L.L. Ochoa, G.W. Richardson, and E.P. Trulock Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome J Heart Lung Transplant 15 1996 100 105
32. G.P. Diller, K. Dimopoulos, C.S. Broberg, M.G. Kaya, U.S. Naghotra, and A. Uebing Presentation, survival prospects, and predictors of death in Eisenmenger syndrome: a combined retrospective and case-control study Eur Heart J 27 2006 1737 1742
33. L. Daliento, J. Somerville, P. Presbitero, L. Menti, S. Brach-Prever, and G. Rizzoli Eisenmenger syndrome. Factors relating to deterioration and death Eur Heart J 19 1998 1845 1855
34. G.P. Diller, K. Dimopoulos, D. Okonko, W. Li, S.V. Babu-Narayan, and C.S. Broberg Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implication Circulation 112 2005 828 835
35. G.P. Diller, and M.A. Gatzoulis Pulmonary vascular disease in adults with congenital heart disease Circulation 115 2007 1039 1050
36. J. Deanfield, E. Thaulow, C. Warnes, G. Webb, F. Kolbel, and A. Hoffman Management of grown up congenital heart disease Eur Heart J 24 2003 1035 1084 (Pubitemid 36717120)
37. C. Broberg, M. Ujita, S. Babu-Narayan, M. Rubens, S.K. Prasad, and J.S. Gibbs Massive pulmonary artery thrombosis with haemoptysis in adults with Eisenmenger's syndrome: a clinical dilemma Heart 90 2004 e63
38. C.S. Broberg, M. Ujita, S. Prasad, W. Li, M. Rubens, and B.E. Bax Pulmonary arterial thrombosis in Eisenmenger syndrome is associated with biventricular dysfunction and decreased pulmonary flow velocity J Am Coll Cardiol 50 2007 634 642
39. W. Vongpatanasin, M.E. Brickner, L.D. Hillis, and R.A. Lange The Eisenmenger syndrome in adults Ann Intern Med 128 1998 745 755
40. L. Swan, M. Lupton, J. Anthony, S.M. Yentis, P.J. Steer, and M.A. Gatzoulis Controversies in pregnancy and congenital heart disease Congenit Heart Dis 1 2006 27 34
41. E. Bedard, K. Dimopoulos, and M.A. Gatzoulis Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension? Eur Heart J 30 2009 256 265
42. L.J. Rubin, D.B. Badesch, R.J. Barst, N. Galie, C.M. Black, and A. Keogh Bosentan therapy for pulmonary arterial hypertension N Engl J Med 346 2002 896 903 (Pubitemid 34984638)
43. R. Barst, D. Langleben, D. Badesch, A. Frost, E.C. Lawrence, and S. Shapiro Treatment of pulmonary arterial hypertension with the selective endothelin A receptor antagonist sitaxsentan J Am Coll Cardiol 47 2006 2049 2056
44. N. Galie, H. Olschewski, R.J. Oudiz, F. Torres, A. Frost, and H.A. Ghofrani Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2 Circulation 117 2008 3010 3019
45. N. Gali, M. Beghetti, M.A. Gatzoulis, J. Granton, R.M. Berger, and A. Lauer Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study Circulation 114 2006 48 54
46. M.A. Gatzoulis, M. Beghetti, N. Galie, J. Granton, R.M. Berger, and A. Lauer Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study Int J Cardiol 127 2008 27 32
47. D.D. Christensen, M.E. McConnell, W.M. Book, and W.T. Mahle Initial experience with bosentan therapy in patients with the Eisenmenger syndrome Am J Cardiol 94 2004 261 263
48. M.A. Gatzoulis, P. Rogers, W. Li, C. Harries, D. Cramer, and S. Ward Safety and tolerability of bosentan in adults with Eisenmenger physiology Int J Cardiol 98 2005 147 151
49. D. Poindron, F. Godart, A. Duhamel, A. Richard, C. Francart, and G.M. Breviere The effect of an endothelin receptor antagonist in Eisenmenger syndrome: a single-center experience of 11 patients Arch Mal Coeur Vaiss 99 2006 457 462
50. H. Brun, E. Thaulow, P.M. Fredriksen, and H. Holmstrom Treatment of patients with Eisenmenger's syndrome with Bosentan Cardiol Young 17 2007 288 294
51. G.P. Diller, K. Dimopoulos, M.G. Kaya, C. Harries, A. Uebing, and W. Li Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease Heart 93 2007 974 976
52. M. D'Alto, C.D. Vizza, E. Romeo, R. Badagliacca, G. Santoro, and R. Poscia Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical, and haemodynamic effect Heart 93 2007 621 625
53. R.L. Van Loon, E.S. Hoendermis, M.G. Duffels, A. Vonk-Noordegraaf, B.J. Mulder, and H.L. Hillege Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist? Am Heart J 154 2007 776 782
54. R.M. Berger, M. Beghetti, N. Gali, M.A. Gatzoulis, J. Granton, and A. Lauer Atrial septal defects versus ventricular septal defects in BREATHE-5, a placebo-controlled study of pulmonary arterial hypertension related to Eisenmenger's syndrome: A subgroup analysis Int J Cardiol 20 2009 [Epub ahead of print]
55. E.M. Chau, K.Y. Fan, and W.H. Chow Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension Int J Cardiol 120 2007 301 305
56. N. Garg, M.K. Sharma, and N. Sinha Role of oral sildenafil in severe pulmonary arterial hypertension: clinical efficacy and dose response relationship Int J Cardiol 120 2007 306 313
57. K. Okyay, M. Cemri, B. Boyac, R. Yalcn, and A. Cengel Use of long-term combined therapy with inhaled iloprost and oral sildenafil in an adult patient with eisenmenger syndrome Cardiol Rev 13 2005 312 314
58. T.P. Singh, M. Rohit, A. Grover, S. Malhotra, and R. Vijayvergiya A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension Am Heart J 151 851 2006 e1 e5
59. Z.S. Lim, A.P. Salmon, J.J. Vettukattil, and G.R. Veldtman Sildenafil therapy for pulmonary arterial hypertension associated with atrial septal defects Int J Cardiol 118 2007 178 182
60. S. Mukhopadhyay, M. Sharma, S. Ramakrishnan, J. Yusuf, M.D. Gupta, and N. Bhamri Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a preliminary observational study Circulation 114 2006 1807 1810
61. E.L. Tay, M. Papaphylactou, G.P. Diller, R. Alonso-Gonzalez, R. Inuzuka, and G. Giannakoulas Quality of life and functional capacity can be improved in patients with Eisenmenger syndrome with oral sildenafil therapy Int J Cardiol 2010 [Epub ahead of print]
62. E.B. Rosenzweig, D. Kerstein, and R.J. Barst Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects Circulation 99 1999 1858 1865
63. S.M. Fernandes, J.W. Newburger, P. Lang, D.D. Pearson, J.A. Feinstein, and K. Gauvreau Usefulness of epoprostenol therapy in the severely ill adolescent/adult with Eisenmenger physiology Am J Cardiol 91 2003 632 635
64. H.P. Gildein, A. Wildberg, and R. Mocellin Comparative studies of hemodynamics under prostacyclin and nifedipine in patients with Eisenmenger syndrome Z Kardiol 84 1995 55 63
65. K. Dimopoulos, R. Inuzuka, S. Goletto, G. Giannakoulas, L. Swan, and S.J. Wort Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension Circulation 121 2010 20 25
66. T.K. Waddell, L. Bennett, R. Kennedy, T.R. Todd, and S.H. Keshavjee Heart-lung or lung transplantation for Eisenmenger syndrome J Heart Lung Transplant 21 2002 731 737
67. E.B. Berman, and R.J. Barst Eisenmenger's syndrome: current management Prog Cardiovasc Dis 45 2002 129 138
68. S.C. Stoica, K.D. McNeil, K. Perreas, L.D. Sharples, D.K. Satchithananda, and S.S. Tsui Heart-lung transplantation for Eisenmenger syndrome: early and long-term results Ann Thorac Surg 72 2001 1887 1891
69. T. Adriaenssens, M. Delcroix, K. Van Deyk, and W. Budts Advanced therapy may delay the need for transplantation in patients with the Eisenmenger syndrome Eur Heart J 27 2006 1472 1477
70. N.S. Ghanayem, S. Berger, and J.S. Tweddell Medical management of the failing Fontan Pediatr Cardiol 28 2007 465 471
71. A.A. Kouatli, J.A. Garcia, T.M. Zellers, E.M. Weinstein, and L. Mahony Enalapril does not enhance exercise capacity in patients after Fontan procedure Circulation 96 1997 1507 1512
72. A. Gamillscheg, G. Zobel, B. Urlesberger, J. Berger, D. Dacar, and J.I. Stein Inhaled nitric oxide in patients with critical pulmonary perfusion after Fontan-type procedures and bidirectional Glenn anastomosis J Thorac Cardiovasc Surg 113 1997 435 442
73. K. Takahashi, Y. Mori, H. Yamamura, T. Nakanishi, and M. Nakazawa Effect of beraprost sodium on pulmonary vascular resistance in candidates for a Fontan procedure: a preliminary study Pediatr Int 45 2003 671 675
74. K. Miyaji, N. Nagata, T. Miyamoto, and K. Kitahori Combined therapy with inhaled nitric oxide and intravenous epoprostenol (prostacyclin) for critical pulmonary perfusion after the Fontan procedure J Thorac Cardiovasc Surg 125 2003 437 439
75. S. Khambadkone, J. Li, M.R. De Leval, S. Cullen, J.E. Deanfield, and A.N. Redington Basal pulmonary vascular resistance and nitric oxide responsiveness late after Fontan-type operation Circulation 107 2003 3204 3208
76. A. Giardini, A. Balducci, S. Specchia, G. Gargiulo, M. Bonvicini, and F.M. Picchio Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients Eur Heart J 29 2008 1681 1687
77. K. Haseyama, G. Satomi, S. Yasukochi, H. Matsui, Y. Harada, and S. Uchita Pulmonary vasodilation therapy with sildenafil citrate in a patient with plastic bronchitis after the Fontan procedure for hypoplastic left heart syndrome J Thorac Cardiovasc Surg 132 2006 1232 1233
78. O. Uzun, J.K. Wong, V. Bhole, and O. Stumper Resolution of protein-losing enteropathy and normalization of mesenteric Doppler flow with sildenafil after Fontan Ann Thorac Surg 82 2006 e39 e40
79. S.C. Apostolopoulou, A. Manginas, D.V. Cokkinos, and S. Rammos Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study Heart 93 2007 350 354
80. C. Ovaert, D. Thijs, D. Dewolf, J. Ottenkamp, H. Dessy, and P. Moons The effect of bosentan in patients with a failing Fontan circulation Cardiol Young 19 2009 331 339